Anixa Biosciences completes dosing of fourth cohort in ovarian cancer CAR-T trial; Early results show promise

Johnson & Johnson's Phase 3 MARIPOSA study shows RYBREVANT and LAZCLUZE prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer

BioMarin reveals positive PALYNZIQ (pegvaliase-pqpz) Phase 3 data in adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism

Nuvalent presents zidesamtinib ARROS-1 clinical trial data for TKI Pre-treated patients with Advanced ROS1-positive NSCLC at WCLC 2025

IDEAYA Biosciences and Hengrui Pharma announce IDE849 (SHR-4849) positive Phase 1 data in small cell lung cancer at IASLC 2025 World Conference on Lung Cancer

Onco3R Therapeutics receives Belgian regulatory approval for clinical trial of novel SIK3 inhibitor

Rakovina Therapeutics announces presentation at H.C. Wainwright 27th Annual Global Investment Conference

Blue Cell Therapeutics appoints Olav Hellebo as board chairman

IDEAYA Biosciences enrols first patient in Phase 1/2 trial of IDE397 and Trodelvy for MTAP-deletion non-small cell lung cancer

ExpreS2ion reports early immune response in first patient from Phase I HER2 breast cancer vaccine trial

Sanofi's amlitelimab delivers positive phase 3 results in atopic dermatitis study

Resolution Therapeutics reports first patient dosed in Phase I/II EMERALD study

enGene completes target enrollment for LEGEND pivotal cohort

IDEAYA Biosciences submits IND for IDE892; Targets Phase 1 in 4Q 2025

Biophytis secures EMA clearance to advance Phase 2 obesity trial